Yellow fever - Pipeline Insight, 2024

Yellow fever - Pipeline Insight, 2024

DelveInsight’s, “Yellow Fever- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Yellow Fever: Understanding

Yellow Fever: Overview

Yellow fever is an acute viral hemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species. The ""yellow"" in the name refers to the jaundice that affects some patients. The virus is endemic in tropical areas of Africa and Central and South America. Large epidemics of yellow fever occur when infected people introduce the virus into heavily populated areas with high mosquito density and where most people have little or no immunity, due to lack of vaccination. In these conditions, infected mosquitoes of the Aedes aegypti species transmit the virus from person to person.

Yellow fever is prevented by an extremely effective vaccine, which is safe and affordable. A single dose of yellow fever vaccine is sufficient to grant sustained immunity and life-long protection against yellow fever disease. A booster dose of the vaccine is not needed.

The majority of people infected with yellow fever virus will either not have symptoms, or have mild symptoms and completely recover. Yellow fever appears with a sudden onset of fever, chills, headache, backache, nausea, and vomiting and yellow skin. Serious cases may cause fatal heart, liver and kidney conditions, lower back pain, dizziness, and abdominal pain. No specific treatment for the disease exists. Efforts focus on managing symptoms and limiting complications.

Yellow fever is difficult to diagnose, especially during the early stages. More commonly it is diagnosed based on laboratory testing, a person’s symptoms, and travel history. Good and early supportive treatment in hospitals improves survival rates. There is no medicine to treat or cure infection from yellow fever. Vaccination is the most important means of preventing yellow fever. Patients with severe symptoms of yellow fever infection should be hospitalized for close observation and supportive care.

""Yellow Fever- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Yellow Fever pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Yellow Fever R&D. The therapies under development are focused on novel approaches to treat/improve Yellow Fever.

Yellow Fever Emerging Drugs Chapters

This segment of the Yellow Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Yellow Fever Emerging Drugs

SP0218 : Sanofi

SP0218 is a subcutaneous formulation of a yellow fever vaccine being developed by Sanofi for the prevention of yellow fever. The drug is currently in Phase II stage of clinical trials for the evaluation of Yellow fever.

HydroVax-002 YFV : Najít Technologies

HydroVax-002 YFV is a novel inactivated vaccine which acts by stimulating the immune response. The vaccine candidate is based on HydroVax technology. It is administered through intramuscular route. The drug is currently in Phase I stage of clinical trials for the evaluation of Yellow fever.

Further product details are provided in the report……..

Yellow Fever: Therapeutic Assessment

This segment of the report provides insights about the different Yellow Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Yellow Fever

There are approx. 3+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. phase II include, Sanofi

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Yellow Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Yellow Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Yellow Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Yellow Fever drugs.

Yellow Fever Report Insights

Yellow Fever Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Yellow Fever Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Yellow Fever drugs?

How many Yellow Fever drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Yellow Fever?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Yellow Fever therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Yellow Fever and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sanofi

Najit Technologies, Inc.

Emergex Vaccines

Key Products

SP0218

HydroVax-002 YFV

Research programme: yellow fever booster vaccine